newsfilter
← Latest News
PR Newswire·

New Three-Year Real-World LEQEMBI® Data Presented at CTAD 2026

  • Eisai and Biogen announced three-year real-world findings from the LEADER study involving 560 patients across 13 U.S. clinical sites.
  • LEQEMBI treatment showed a 76% lower rate of progression to moderate or severe Alzheimer's disease dementia compared to a matched natural history cohort over 36 months.
  • 81.1% of assessed patients remained stable or improved after an average of 18 months of treatment.
  • Statistical modeling estimates that 95.0% of patients receiving LEQEMBI remain in the early stages of Alzheimer's disease through three years of treatment.
  • Complete amyloid clearance was observed in 77% of patients (33 of 43) who had both baseline and follow-up amyloid PET data at a median of 18.1 months.
  • Treatment persistence was high, with 87.5% of all patients remaining on LEQEMBI at the time of chart extraction and an average treatment duration of 19 months.
  • Of patients reaching 18 months of treatment, 91.7% remained on therapy, with transitions observed to once-every-four-weeks IV maintenance and once-weekly subcutaneous maintenance.
  • Subcutaneous maintenance therapy showed no ARIA events reported, while IV maintenance reported a 0.5% incidence of isolated ARIA-H.
  • Clinical outcomes regarding stability or improvement were consistent between sexes, with 79.3% of women and 83.3% of men showing positive results.
  • ARIA incidence and severity were generally consistent between female and male patients across all subtypes.
  • LEADER safety findings aligned with the independent ALZ-NET registry and U.S. prescribing information for LEQEMBI.
  • A separate international meta-analysis of approximately 5,000 patients across six countries reported lower ARIA rates than those seen in the Clarity AD clinical trial.
  • The meta-analysis found a pooled average total ARIA rate of 12.4%, a symptomatic ARIA rate of 0.8%, and a treatment discontinuation rate due to adverse events of 3.2%.
Company
Eisai Inc.
Keywords
Eisai Inc.